Welcome to our dedicated page for bioAffinity Tech SEC filings (Ticker: BIAFW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
bioAffinity Technologies, Inc. filings document a public biotechnology company with common stock and tradeable warrants listed on Nasdaq. Recent reports include Form 8-K disclosures for quarterly financial information, CyPath® Lung clinical case-study announcements, annual meeting voting results, director elections, and amendments to the company’s equity incentive compensation plan.
Registration statements and current reports also describe the company’s emerging growth and smaller reporting company status, securities offerings, capital structure, and governance matters associated with its noninvasive lung-disease diagnostics business. The filing record ties operating disclosures to CyPath® Lung, Precision Pathology Laboratory Services, laboratory-developed test commercialization, and the company’s research platform for lung disease diagnostics.
bioAffinity Technologies, Inc. (symbol BIAFW) has submitted a post-effective amendment on Form POS AM. The excerpt provided is almost entirely made up of XBRL tag references that map the company’s equity classes, incentive plans, warrants and other membership interests across various reporting periods. No narrative discussion, transaction description, or quantitative financial statements accompany the tags. As presented, the amendment appears to be an administrative update to existing registration statements—likely refreshing or re-labeling warrant-related securities—rather than announcing new capital raises or operational developments.
Because the filing lacks earnings data, cash-flow details, or material corporate actions, it offers no immediate insight into profitability, liquidity, or strategy. For investors, the document’s impact is therefore minimal unless later supplemented by a prospectus or pricing information that changes dilution expectations.
bioAffinity Technologies has filed a POS AM (Post-Effective Amendment) related to their warrant securities (BIAFW). The filing includes several key warrant-related developments:
- Multiple Warrant Offerings: The company has various warrant classes including tradeable and non-tradeable warrants, pre-IPO convertible notes, and placement agent warrants
- Recent Warrant Activity: Notable warrant transactions occurred in March 2024, August 2024, and October 2024, with additional warrant inducement events in February 2025
- Equity Incentive Plans: The company maintains both 2014 and 2024 equity incentive plans, including restricted stock units (RSUs) and stock options for employees, non-employees, and board members
- Financial Structure: The filing details the company's capital structure including common stock, preferred stock, and various warrant classifications with their respective terms and conditions
This amendment appears to update and clarify the terms and conditions of the company's outstanding warrants and related securities, ensuring compliance with SEC regulations and providing updated information to investors.